Journal article

Peptide Receptor Radionuclide Therapy with Cu-67-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model

Carleen Cullinane, Charmaine M Jeffery, Peter D Roselt, Ellen M van Dam, Susan Jackson, Kevin Kuan, Price Jackson, David Binns, Jessica van Zuylekom, Matthew J Harris, Rodney J Hicks, Paul S Donnelly

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2020


Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors. The diagnostic and therapeutic potential of 64Cu and 67Cu, respectively, offers the possibility of using a single somatostatin receptor-targeted peptide conjugate as a theranostic agent. A sarcophagine cage amine ligand, MeCOSar (5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid), conjugated to (Tyr3)-octreotate, called 64Cu-CuSarTATE, was demonstrated to be an imaging agent and potential prospective dosimetry tool in 10 patients with neuroendocrine tumors. This study aimed to explore the antit..

View full abstract